38,061 Shares in Haleon plc (NYSE:HLN) Acquired by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC bought a new position in shares of Haleon plc (NYSE:HLN) during the second quarter, HoldingsChannel.com reports. The firm bought 38,061 shares of the company’s stock, valued at approximately $314,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Profund Advisors LLC raised its stake in shares of Haleon by 3.0% in the second quarter. Profund Advisors LLC now owns 53,889 shares of the company’s stock valued at $445,000 after acquiring an additional 1,563 shares in the last quarter. Sei Investments Co. raised its position in Haleon by 2.7% in the 2nd quarter. Sei Investments Co. now owns 802,507 shares of the company’s stock valued at $6,629,000 after purchasing an additional 21,418 shares in the last quarter. AE Wealth Management LLC boosted its stake in shares of Haleon by 6.1% in the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock valued at $159,000 after buying an additional 1,098 shares during the period. Benjamin F. Edwards & Company Inc. grew its position in shares of Haleon by 16.6% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 49,385 shares of the company’s stock worth $408,000 after buying an additional 7,026 shares in the last quarter. Finally, First Eagle Investment Management LLC increased its stake in shares of Haleon by 36.8% during the second quarter. First Eagle Investment Management LLC now owns 1,862,056 shares of the company’s stock worth $15,381,000 after buying an additional 501,035 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of recent research reports. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank assumed coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. Finally, Morgan Stanley increased their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Haleon has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Performance

Shares of HLN opened at $10.67 on Wednesday. The company has a market capitalization of $48.72 billion, a price-to-earnings ratio of 35.57, a price-to-earnings-growth ratio of 3.10 and a beta of 0.26. Haleon plc has a 52-week low of $7.70 and a 52-week high of $10.76. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average price of $9.84 and a 200 day moving average price of $8.91.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The company had revenue of $3.50 billion during the quarter, compared to analysts’ expectations of $3.55 billion. During the same period last year, the business earned $0.08 earnings per share. Research analysts predict that Haleon plc will post 0.46 EPS for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were issued a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s payout ratio is currently 33.33%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.